Stemline Therapeutics, Inc. (NASDAQ:STML) COO Kenneth Hoberman sold 11,983 shares of Stemline Therapeutics stock in a transaction on Monday, December 18th. The shares were sold at an average price of $14.18, for a total value of $169,918.94. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Kenneth Hoberman also recently made the following trade(s):

  • On Friday, December 15th, Kenneth Hoberman sold 11,943 shares of Stemline Therapeutics stock. The shares were sold at an average price of $14.18, for a total value of $169,351.74.

Stemline Therapeutics, Inc. (NASDAQ:STML) traded down $0.55 on Wednesday, hitting $13.90. The stock had a trading volume of 124,200 shares, compared to its average volume of 273,463. Stemline Therapeutics, Inc. has a 1 year low of $5.50 and a 1 year high of $16.00.

A number of equities research analysts have weighed in on STML shares. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. HC Wainwright restated a “buy” rating and set a $34.00 price target on shares of Stemline Therapeutics in a research report on Tuesday, September 12th. Finally, BidaskClub downgraded Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Stemline Therapeutics currently has an average rating of “Hold” and a consensus target price of $33.75.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Lyon Street Capital LLC grew its stake in shares of Stemline Therapeutics by 331.1% in the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock worth $6,010,000 after purchasing an additional 415,867 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Stemline Therapeutics by 32.9% in the first quarter. Vanguard Group Inc. now owns 825,153 shares of the biopharmaceutical company’s stock worth $7,055,000 after purchasing an additional 204,228 shares during the last quarter. AXA grew its stake in shares of Stemline Therapeutics by 44.9% in the second quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock worth $5,789,000 after purchasing an additional 195,022 shares during the last quarter. C WorldWide Group Holding A S bought a new stake in shares of Stemline Therapeutics in the third quarter worth about $1,776,000. Finally, Artal Group S.A. grew its stake in shares of Stemline Therapeutics by 150.0% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock worth $2,300,000 after purchasing an additional 150,000 shares during the last quarter. Hedge funds and other institutional investors own 50.24% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/stemline-therapeutics-inc-stml-coo-kenneth-hoberman-sells-11983-shares/1774753.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.